WallStSmart

Coinbase Global Inc (COIN)vsPfizer Inc (PFE)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Pfizer Inc generates 820% more annual revenue ($63.32B vs $6.88B). COIN leads profitability with a 18.3% profit margin vs 11.8%. COIN appears more attractively valued with a PEG of 0.78. COIN earns a higher WallStSmart Score of 60/100 (C).

COIN

Buy

60

out of 100

Grade: C

Growth: 7.3Profit: 6.5Value: 5.0Quality: 6.0
Piotroski: 2/9Altman Z: 1.78

PFE

Buy

55

out of 100

Grade: C

Growth: 3.3Profit: 7.0Value: 5.3Quality: 4.8
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for COIN.

PFEUndervalued (+29.4%)

Margin of Safety

+29.4%

Fair Value

$37.48

Current Price

$25.68

$11.80 discount

UndervaluedFair: $37.48Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COIN4 strengths · Avg: 8.8/10
EPS GrowthGrowth
430.6%10/10

Earnings expanding 430.6% YoY

Market CapQuality
$50.96B9/10

Large-cap with strong market position

PEG RatioValuation
0.788/10

Growing faster than its price suggests

Free Cash FlowQuality
$3.07B8/10

Generating 3.1B in free cash flow

PFE4 strengths · Avg: 8.8/10
Operating MarginProfitability
31.6%10/10

Strong operational efficiency at 31.6%

Market CapQuality
$150.92B9/10

Large-cap with strong market position

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$2.18B8/10

Generating 2.2B in free cash flow

Areas to Watch

COIN4 concerns · Avg: 2.8/10
Altman Z-ScoreHealth
1.784/10

Distress zone — elevated risk

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
70.9x2/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
-22.2%2/10

Revenue declined 22.2%

PFE3 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
13.772/10

Expensive relative to growth rate

EPS GrowthGrowth
-10.1%2/10

Earnings declined 10.1%

Comparative Analysis Report

WallStSmart Research

Bull Case : COIN

The strongest argument for COIN centers on EPS Growth, Market Cap, PEG Ratio. Profitability is solid with margins at 18.3% and operating margin at 11.3%. PEG of 0.78 suggests the stock is reasonably priced for its growth.

Bull Case : PFE

The strongest argument for PFE centers on Operating Margin, Market Cap, Price/Book.

Bear Case : COIN

The primary concerns for COIN are Altman Z-Score, Piotroski F-Score, P/E Ratio. A P/E of 70.9x leaves little room for execution misses.

Bear Case : PFE

The primary concerns for PFE are Piotroski F-Score, PEG Ratio, EPS Growth.

Key Dynamics to Monitor

COIN profiles as a declining stock while PFE is a value play — different risk/reward profiles.

COIN carries more volatility with a beta of 3.38 — expect wider price swings.

PFE is growing revenue faster at 5.4% — sustainability is the question.

COIN generates stronger free cash flow (3.1B), providing more financial flexibility.

Bottom Line

COIN scores higher overall (60/100 vs 55/100), backed by strong 18.3% margins. PFE offers better value entry with a 29.4% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Coinbase Global Inc

FINANCIAL SERVICES · FINANCIAL DATA & STOCK EXCHANGES · USA

Coinbase Global, Inc. provides financial infrastructure and technology for the crypto economy. The company is headquartered in Wilmington, Delaware.

Visit Website →

Pfizer Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The name of the company commemorates its co-founder, Charles Pfizer (1824-1906). Pfizer develops and produces medicines and vaccines for immunology, oncology, cardiology, endocrinology, and neurology. The company has several blockbuster drugs or products that each generate more than 1 billion USD in annual revenues.

Visit Website →

Want to dig deeper into these stocks?